$PEPG News

Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11

PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PepGen Files For $400M Shelf Registration And $100M At-The-Market Stock Offering

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $4

PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5

PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

PepGen shares are trading lower after the company announced clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. Also, Wedbush lowered its price target on the stock from $9 to $5.

PepGen shares are trading lower after the company announced clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. Also, Wedbush lowered its price target on the stock from $9 to $5.

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5

Why Is PepGen Stock Sinking Tuesday?

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data - Slideshow

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

PepGen Announces Clinical Data From The 5 Mg/Kg Multiple Ascending Dose Cohort Of The Ongoing Phase 2 FREEDOM2-DM1 Trial In Patients With Myotonic Dystrophy Type 1; PGN-EDOM1 Was Generally Well-Tolerated With All Adverse Events Mild Or Moderate And No Serious Adverse Events Reported